SCHEMBL23975365

SCHEMBL23975365

O=C(CCOCCOCCOCCOCCNC1CCCC1)NCCOCCOCCNC(=O)C1CCCCC1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.44
NPC1 O15118 1/20 0.44
PKM P14618 1/20 0.44
EPHX2 P34913 1/20 0.44
RAB9A P51151 1/20 0.44
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
CHRM1 P11229 2/20 0.41
NAAA Q02083 1/20 0.40
EPHX1 P07099 1/20 0.39
KEAP1 Q14145 1/20 0.36
NFE2L2 Q16236 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
FOXM1 Q08050 2/20 0.36
CXCR4 P61073 1/20 0.35
KDM4E B2RXH2 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21842360 1.00 SMN1; SMN2 (0.44) SMN1; SMN2NPC1PKMEPHX2RAB9A
SCHEMBL23975361 1.00 SMN1; SMN2 (0.44) SMN1; SMN2NPC1PKMEPHX2RAB9A
SCHEMBL23975140 0.94 NAAA (0.50) SMN1; SMN2NPC1PKMEPHX2RAB9A
SCHEMBL21842289 0.94 NAAA (0.50) SMN1; SMN2NPC1PKMEPHX2RAB9A
SCHEMBL23975359 0.94 NAAA (0.50) SMN1; SMN2NPC1PKMEPHX2RAB9A
SCHEMBL23975357 0.92 SMN1; SMN2 (0.50) SMN1; SMN2NPC1PKMEPHX2RAB9A
SCHEMBL23975143 0.90 SMN1; SMN2 (0.48) SMN1; SMN2NPC1PKMEPHX2RAB9A
SCHEMBL26158778 0.87 SMN1; SMN2 (0.48) SMN1; SMN2NPC1PKMEPHX2RAB9A
SCHEMBL21842300 0.85 KDM4E (0.39) SMN1; SMN2EPHX2KMT2AEPHX1L3MBTL1
SCHEMBL24244844 0.83 SMN1; SMN2 (0.58) SMN1; SMN2NPC1PKMEPHX2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210338825-A1 DEGRADERS OF HEPATITIS C VIRUS NS3/4A PROTEIN DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210338825-A1 DEGRADERS OF HEPATITIS C VIRUS NS3/4A PROTEIN HAVCR2, CUL4A, PSMC3 SMN1; SMN2 3617/4885NPC1 734/4885PKM 3807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.